The Rise and Fall of the Biotech Bubble in the Early 1990s

John Smith

The early 1990s saw a dramatic boom and bust in biotechnology stocks, known as the Biotech Bubble. Between late 1992 and early 1993, the biotech sector experienced a period of rapid growth followed by a steep decline, impacting the broader stock market and economic conditions at the time.

The Emergence of the Biotech Industry

The biotechnology industry first emerged in the 1970s and 1980s with the advent of new techniques for manipulating DNA and proteins to develop medical treatments and applications. Companies focused on recombinant DNA, monoclonal antibodies, and genomics drove innovation and investment in the nascent industry.

Venture capital investment in biotech took off in the early 1990s. Several factors contributed to the rise of biotech companies during this period:

  • Scientific breakthroughs like PCR dna amplification and automated DNA sequencing enabled new product development.
  • The AIDS crisis and demand for new treatments spurred research spending.
  • The Bayh-Dole Act of 1980 allowed universities to patent federally funded research, encouraging tech transfer and spin-offs.
  • There were reforms in FDA drug approval which helped innovative drugs reach the market.
  • Investor enthusiasm grew around the potential for biotech to deliver high growth and profits.

The Biotech Boom of 1992-1993

Fueled by the prospects of biotech, investment and speculation dramatically increased in 1992 and 1993 resulting in abubble. Several key events occurred during the boom:

  • In 1991, Amgen’s drug Epogen was approved to treat anemia, showcasing biotech’s potential. Amgen’s stock quadrupled between 1990 and 1992.
  • In 1992, Genentech’s stock price doubled following the IPO of its majority owner Roche. Genentech’s diabetes drug Activase generated billions in revenue.
  • The NASDAQ Biotechnology Index was introduced in 1993. It started at 800 and climbed to 1,200 by the end of 1993, a 50% increase in less than a year.
  • Dozens of new biotech firms conducted IPOs raising billions in capital. Most had no approved products yet, just promising drug candidates.
  • Venture capital investment in biotech startups went from $750 million in 1991 to over $2 billion in 1992.

The biotech sector’s rapid growth significantly impacted the broader stock market. The Dow Jones Industrial Average, after reaching 3,000 in 1991, hit 3,600 by early 1993 propelled by biotech and other technology stocks. For a period, biotech represented 20% of the entire NASDAQ exchange.

The Biotech Bubble Bursts in 1993

After climbing Meteorically in 1992 and early 1993, biotech stocks crashed as investor sentiment shifted. Several factors contributed to the downturn:

  • Biotech firms failed to meet overly optimistic growth and earnings projections, leading investors to sour on the sector.
  • Several high profile clinical trial failures eroded confidence in upstart biotechs.
  • The FDA pushed back on commercialization timelines for genomics and other emerging technologies.
  • Broader skepticism grew around whether research would translate into profits.

In the second quarter of 1993, the NASDAQ Biotech index plunged from over 1,200 to around 800, wiping out nearly $18 billion in stock value. Amgen lost half its market value, falling from $32 billion to $16 billion. Many small biotechs saw shares fall over 90%.

The biotech bust impacted broader markets. The Dow gave up its gains from 1992-1993 falling back below 3,600. Economic growth slowed from 7% in 1992 down to 2.7% in 1993, in part due to declines in healthcare and tech sectors.

Aftermath and Impact on Biotech

In the aftermath of the biotech bubble bursting, investor enthusiasm for biotech cooled considerably through the mid 1990s. Many biotech firms could not raise additional capital, leading to consolidations and closures. However, those companies with approved products and solid technology survived the downturn.

Importantly, the biotech sector continued to expand after its first bubble. Understanding of genomics, proteomics, and bioinformatics kept advancing. By the late 1990s, the industry was back in growth mode.

Today biotechnology represents a massive global industry, with most major pharmacutical companies relying on biotech research. While speculation and overinvestment contributed to the 1990s biotech bubble, the underlying science retained its potential to generate medical breakthroughs and strong businesses. The boom and bust was part of the evolution of what has become a pivotal technology field.


  1. Pisano, G.P. (2006). Science Business: The Promise, the Reality, and the Future of Biotech. Harvard Business Review Press.
  2. Rabinow, P. (1996). Making PCR: A Story of Biotechnology. University of Chicago Press.
  3. Galambos, L. and Sturchio, J.L. (1998). Pharmaceutical Firms and the Transition to Biotechnology: A Study in Strategic Innovation. Business History Review, 72(2), 250-278.
  4. Mowery, D.C. et al. (2004). Ivory Tower and Industrial Innovation: University-Industry Technology Transfer Before and After the Bayh-Dole Act. Stanford Business Books.
  5. Daemmrich, A. and Bowden, M. (2005). A Short History of Pharmaceutical Regulation in the United States. Pharmaceutical Policy and Law, 6, 29-57.
  6. Breen, B. (2004). Imagining The Pharmaceutical Industry: Patterns Of Historical Development In The Field Of Pharmaceuticals. Pharmaceutical Products Press.
  7. Pollack, A. (1992, August 25). Amgen’s Stock Price Makes Big Gain. The New York Times.
  8. Pollack, A. (1993, January 11). Roche To Buy 60% Of Genentech For $2.1 Billion. The New York Times.
  9. Reier, S. (2005). Biotech Financing Cycle Turns. Nature Biotechnology, 23(3), 384-385.
  10. Lerner, J. and Merges, R.P. (1998). The Control of Technology Alliances: An Empirical Analysis of the Biotechnology Industry. The Journal of Industrial Economics, 46(2), 125-156.
  11. Ernst & Young LLP (2000). Convergence: The Biotechnology Industry Report.
  12. Fabrikant, G. (1993, January 29). Market Place; biotech stocks continue their decline, depressing overall market. The New York Times.
  13. Nellis, S. (2006). Professional Investor, 11(3), 50-54.
  14. Rosenberg, H. (2002). The Bioscience Economy: Driving New York’s Technology Sector. Center for an Urban Future.
  15. McNamee, M. and Ledley, F.D. (2012). Sustainability of research and development in the pharmaceutical industry. Nature Biotechnology, 30(1), 22-25.
  16. Goozner, M. (2004). Unrevealed: The Mystique of the World’s Biggest Biotech. Center for Science in the Public Interest.
  17. Pisano, G.P. (2006). Can Science Be a Business? Lessons from Biotech. Harvard Business Review, 84(10), 114-125.
  18. NAREIT (2008). REITs: Building Dividends For Your Portfolio.
  19. Malkiel, B.G. (2015). Bubbles in Asset Prices. Princeton University.
  20. Orsenigo, L., Pammolli, F., and Riccaboni, M. (2001). Technological change and network dynamics: Lessons from the pharmaceutical industry. Research Policy, 30(3), 485-508.
  21. McNamee, L.M. and Ledley, F.D. (2017). Patterns of technological innovation in biotech. Nature Biotechnology, 35(10), 937-943.
  22. Pisano, G.P. (2006). Can Science Be a Business? Harvard Business Review
Share This Article
John Smith is a veteran stock trader with over 10 years of experience in the financial markets. He is a widely followed market commentator known for his astute analysis and accurate predictions. John has authored multiple bestselling books explaining complex market concepts in simple terms for novice investors looking to grow their wealth through strategic trading and long-term investments.
Leave a comment